851 related articles for article (PubMed ID: 17233848)
1. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
[TBL] [Abstract][Full Text] [Related]
3. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
Vichinsky E; Pakbaz Z; Onyekwere O; Porter J; Swerdlow P; Coates T; Lane P; Files B; Mueller BU; Coïc L; Forni GL; Fischer R; Marks P; Rofail D; Abetz L; Baladi JF
Acta Haematol; 2008; 119(3):133-41. PubMed ID: 18408362
[TBL] [Abstract][Full Text] [Related]
6. Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.
Cancado R; Olivato MC; Bruniera P; Szarf G; de Moraes Bastos R; Rezende Melo M; Chiattone C
Acta Haematol; 2012; 128(2):113-8. PubMed ID: 22760067
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of deferasirox.
Cappellini MD
Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox for managing iron overload in people with thalassaemia.
Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
Vichinsky E; Bernaudin F; Forni GL; Gardner R; Hassell K; Heeney MM; Inusa B; Kutlar A; Lane P; Mathias L; Porter J; Tebbi C; Wilson F; Griffel L; Deng W; Giannone V; Coates T
Br J Haematol; 2011 Aug; 154(3):387-97. PubMed ID: 21592110
[TBL] [Abstract][Full Text] [Related]
10. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
Shashaty G; Frankewich R; Chakraborti T; Choudary J; Al-Fayoumi S; Kacuba A; Castillo S; Robie-Suh K; Rieves D; Weiss K; Pazdur R
Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
[TBL] [Abstract][Full Text] [Related]
11. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
Cappellini MD; Cohen A; Piga A; Bejaoui M; Perrotta S; Agaoglu L; Aydinok Y; Kattamis A; Kilinc Y; Porter J; Capra M; Galanello R; Fattoum S; Drelichman G; Magnano C; Verissimo M; Athanassiou-Metaxa M; Giardina P; Kourakli-Symeonidis A; Janka-Schaub G; Coates T; Vermylen C; Olivieri N; Thuret I; Opitz H; Ressayre-Djaffer C; Marks P; Alberti D
Blood; 2006 May; 107(9):3455-62. PubMed ID: 16352812
[TBL] [Abstract][Full Text] [Related]
12. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox for transfusion-related iron overload: a clinical review.
Lindsey WT; Olin BR
Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
15. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
[TBL] [Abstract][Full Text] [Related]
16. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
Tsouana E; Kaya B; Gadong N; Hemmaway C; Newell H; Simmons A; Whitmarsh S; Telfer P
Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox (Exjade) for the treatment of iron overload.
Cappellini MD; Taher A
Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox for managing iron overload in people with thalassaemia.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
